Patient-centric no-option refractory angina management: establishing comprehensive angina relief (CARE) clinics.

IF 1.8 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Balaj Rai, Mehmet Yildiz, Jarrod Frizzell, Odayme Quesada, Timothy D Henry
{"title":"Patient-centric no-option refractory angina management: establishing comprehensive angina relief (CARE) clinics.","authors":"Balaj Rai, Mehmet Yildiz, Jarrod Frizzell, Odayme Quesada, Timothy D Henry","doi":"10.1080/14779072.2025.2488859","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Refractory angina (RA) is a debilitating condition characterized by persistent angina despite optimized medical therapy and limited options for further revascularization, leading to diminished quality of life and increased healthcare utilization. The RA patient population is rapidly expanding with significant unmet needs. Specialty clinics should be developed to focus on the long-term efficacy and safety of clinically available and novel treatment strategies, emphasizing quality of life.</p><p><strong>Areas covered: </strong>Patient-focused Comprehensive Angina Relief (CARE) clinics can enhance care and outcomes by providing individualized management for complex RA. This review summarizes peer-reviewed articles from PubMed and trial data from ClinicalTrials.gov. We discuss the epidemiology and pathophysiology of RA, introduce standardized tools for evaluating angina and psychosocial factors, and address symptom management. We also review treatment options such as risk factor modification, medication, and complex revascularization. Additionally, we explore emerging therapies, including coronary sinus occlusion, regenerative therapy, and neuromodulation for 'no-option' RA.</p><p><strong>Expert opinion: </strong>In the next five years, patients with refractory chest pain with or without coronary artery disease will increasingly be referred to specialty clinics for follow-up. Conducting more randomized control clinical trials with larger population subsets will bring novel therapies to the forefront.</p>","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"113-129"},"PeriodicalIF":1.8000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Cardiovascular Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/14779072.2025.2488859","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Refractory angina (RA) is a debilitating condition characterized by persistent angina despite optimized medical therapy and limited options for further revascularization, leading to diminished quality of life and increased healthcare utilization. The RA patient population is rapidly expanding with significant unmet needs. Specialty clinics should be developed to focus on the long-term efficacy and safety of clinically available and novel treatment strategies, emphasizing quality of life.

Areas covered: Patient-focused Comprehensive Angina Relief (CARE) clinics can enhance care and outcomes by providing individualized management for complex RA. This review summarizes peer-reviewed articles from PubMed and trial data from ClinicalTrials.gov. We discuss the epidemiology and pathophysiology of RA, introduce standardized tools for evaluating angina and psychosocial factors, and address symptom management. We also review treatment options such as risk factor modification, medication, and complex revascularization. Additionally, we explore emerging therapies, including coronary sinus occlusion, regenerative therapy, and neuromodulation for 'no-option' RA.

Expert opinion: In the next five years, patients with refractory chest pain with or without coronary artery disease will increasingly be referred to specialty clinics for follow-up. Conducting more randomized control clinical trials with larger population subsets will bring novel therapies to the forefront.

以患者为中心的无选择难治性心绞痛管理:建立综合心绞痛缓解(CARE)诊所。
难治性心绞痛(RA)是一种衰弱性疾病,其特征是持续心绞痛,尽管有优化的药物治疗和有限的进一步血运重建选择,导致生活质量下降和医疗保健利用率增加。类风湿关节炎患者群体正在迅速扩大,有大量未满足的需求。专科诊所的发展应侧重于临床可用和新颖的治疗策略的长期疗效和安全性,强调生活质量。涵盖领域:以患者为中心的综合心绞痛缓解(CARE)诊所可以通过为复杂的类风湿性关节炎提供个性化的管理来提高护理和结果。这篇综述总结了PubMed上同行评审的文章和ClinicalTrials.gov上的试验数据。我们讨论了类风湿性关节炎的流行病学和病理生理学,介绍了评估心绞痛和心理社会因素的标准化工具,并讨论了症状管理。我们还回顾了治疗方案,如危险因素调整,药物治疗和复杂的血运重建术。此外,我们探索新兴疗法,包括冠状窦闭塞、再生疗法和神经调节治疗“无选择”类风湿性关节炎。专家意见:在未来五年内,伴有或不伴有冠状动脉疾病的难治性胸痛患者将越来越多地转诊到专科诊所进行随访。在更大的人群中进行更多的随机对照临床试验将使新疗法走在前列。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Expert Review of Cardiovascular Therapy
Expert Review of Cardiovascular Therapy CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
3.70
自引率
0.00%
发文量
82
期刊介绍: Expert Review of Cardiovascular Therapy (ISSN 1477-9072) provides expert reviews on the clinical applications of new medicines, therapeutic agents and diagnostics in cardiovascular disease. Coverage includes drug therapy, heart disease, vascular disorders, hypertension, cholesterol in cardiovascular disease, heart disease, stroke, heart failure and cardiovascular surgery. The Expert Review format is unique. Each review provides a complete overview of current thinking in a key area of research or clinical practice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信